A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RESORCE
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 07 Aug 2017 According to a Bayer media release, Dr. Jordi Bruix is a lead investigator of this trial.
    • 07 Aug 2017 According to a Bayer media release, based on the data from this trial, the European Commission (EC) has granted marketing authorization for Stivarga (regorafenib) for the treatment of adult patients with HCC who have been previously treated with Nexavar (sorafenib).
    • 26 Jun 2017 According to a Bayer media release, the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing authorization for Stivarga (regorafenib) tablets for the second-line treatment of patients with unresectable hepatocellular carcinoma (HCC) who have progressed after treatment with cancer chemotherapy. The approval is based on data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top